BioMarin's autoimmune-disease therapy gets orphan-drug status

11/30/2009 | Reuters

The FDA granted orphan-drug designation to BioMarin Pharmaceutical's amifampridine phosphate, a drug for Lambert Eaton Myasthenic Syndrome, an autoimmune condition. "We look forward to meeting with the FDA in early 2010 to determine the necessary regulatory path for amifampridine phosphate in the U.S.," said CEO Jean-Jacques Bienaime.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care